$EIGR down 44% Eiger BioPharmaceuticals Inc. (EIGR) shares dropped more than 40% in premarket trade Tuesday after the company said its pulmonary arterial hypertension drug failed to meet a primary and secondary endpoint both overall and in key subgroups.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.